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PCLINICAL RESEARCH Clinical Trial
Renal Protection for Coronary
Angiography in Advanced Renal
Failure Patients by Prophylactic Hemodialysis
A Randomized Controlled Trial
Po-Tsang Lee, MD,*‡§ Kang-Ju Chou, MD,*‡ Chun-Peng Liu, MD,† Guang-Yuan Mar, MD,†
Chien-Liang Chen, MD,*‡ Chih-Yang Hsu, MD,* Hua-Chang Fang, MD,*‡ Hsiao-Min Chung, MD*
Kaohsiung, Taipei, and Tainan, Taiwan
Objectives We performed a study to determine whether prophylactic hemodialysis reduces contrast nephropathy (CN) after
coronary angiography in advanced renal failure patients.
Background Pre-existing renal failure is the greatest risk factor for CN. Hemodialysis can effectively remove contrast media,
but its effect upon preventing CN is still uncertain.
Methods Eighty-two patients with chronic renal failure, referred for coronary angiography, were assigned randomly to re-
ceive either normal saline intravenously and prophylactic hemodialysis (dialysis group; n  42) or fluid supple-
ment only (control group; n  40).
Results Prophylactic hemodialysis lessened the decrease in creatinine clearance within 72 h in the dialysis group (0.4 
0.9 ml/min/1.73 m2 vs. 2.2  2.8 ml/min/1.73 m2; p  0.001). Compared with the dialysis group, the serum
creatinine concentrations in the control group were significantly higher at day 4 (6.3  2.3 mg/dl vs. 5.1  1.3
mg/dl; p  0.010) and at peak level (6.7  2.7 mg/dl vs. 5.3  1.5 mg/dl; p  0.005). Temporary renal re-
placement therapy was required in 35% of the control patients and in 2% of the dialysis group (p  0.001).
Thirteen percent of the control patients, but none of the dialysis patients, required long-term dialysis after dis-
charge (p  0.018). For the patients not requiring chronic dialysis, 13 patients in the control group (37%) and 2
in the dialysis group (5%) had an increase in serum creatinine concentration at discharge of more than 1 mg/dl
from baseline (p  0.001).
Conclusions Prophylactic hemodialysis is effective in improving renal outcome in chronic renal failure patients undergoing
coronary angiography. (J Am Coll Cardiol 2007;50:1015–20) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.033a
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tontrast nephropathy (CN) is a major complication after
oronary intervention and is the third leading cause of
ospital-acquired acute renal failure (1–4). Because pre-
xisting renal dysfunction is the most important risk factor
1–4), the incidence of acute renal shutdown after coronary
ngiography (CAG) is quite high in patients with chronic
enal failure. It has been reported that when serum creati-
ine (Cr) levels are 4.5 mg/dl, the likelihood of CN
pproaches 100% for diabetic patients and 60% for nondi-
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upported by grants from Kaohsiung Veterans General Hospital (VGHKS93-31) and
he National Science Committee (NSC93-2314-B-075B-012).f
Manuscript received December 6, 2006; revised manuscript received May 18, 2007,
ccepted May 22, 2007.betic patients (5–7). When CN occurs in these high-risk
atients, this could cause temporary renal deterioration or
ead to permanent end-stage renal disease (ESRD) neces-
itating chronic dialysis.
Several interventions have been used to prevent CN, but
nly fluid supplements, low-osmolality contrast, a double
ose of N-acetylcysteine, and reducing the dose of the
ontrast agent have been shown to be effective (8–15).
hese strategies were mainly investigated in the general
opulation or in patients with mild renal insufficiency; methods
or preventing CN in advanced renal failure patients remain
nknown. Additionally, excessive fluid supplement is barely
olerated in patients with renal failure, especially when they
ave poor heart function.
Contrast media are excreted mainly by glomerular filtra-
ion. The elimination is slow in patients with chronic renal
ailure; therefore, it would make these vulnerable patients
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It is known that contrast media
can be effectively removed from
the blood of patients with chronic
renal failure by hemodialysis even
faster than by kidney in normal
subjects (16). Hemodialysis after
contrast media exposure is hy-
pothesized to be helpful in lessen-
ing CN. Therefore, we performed
a prospective, randomized control
rial to examine the efficacy of prophylactic hemodialysis in
he prevention of CN in patients with advanced renal failure
ndergoing coronary procedures.
ethods
articipants. The study was performed between August
003 and June 2006 in Kaohsiung Veterans General Hos-
ital in Taiwan. Patients were considered eligible for the
tudy if they were older than 20 years of age, had been
eferred for coronary angiography, and had a stable Cr
oncentration of more than 3.5 mg/dl with a change of
0.5 mg/dl in 1 month. Criteria for exclusion included
regnancy, lactation, intravascular administration of con-
rast medium within the previous 7 days, treatment with
etformin or nonsteroidal anti-inflammatory drugs within
he previous 48 h, exposure to nephrotoxic drugs within the
revious 7 days, history of serious reactions to the contrast
edium, newly diagnosed unstable diabetes, severe con-
omitant disease, renal transplantation, and ESRD neces-
itating chronic dialysis. Acetylcysteine, theophylline, dopa-
ine, and mannitol were not used during the study.
ngiotensin-converting enzyme inhibitors were allowed but
ere withheld on the day of radiographic investigation. The
thics committee of Kaohsiung Veterans General Hospital
pproved the study protocol, and all patients gave written,
nformed consent.
rocedures. All patients were given intravenous normal
aline at 1 ml/kg/h for 6 h before and 12 h after contrast
edium exposure, and then randomized to receive hemo-
ialysis (dialysis group) or not (control group). In the
ialysis group, dialysis was started as soon as technically
ossible after angiography, and the time interval from
ontrast exposure to initiation of dialysis was recorded.
emodialysis was performed through a double-lumen in-
ravenous femoral catheter placed before coronary angiog-
aphy. The dialyzer was a high-flux polysulfone membrane
BS1.8, Toray Industries, Inc., Tokyo, Japan). The blood
ow was 150 ml/min, the duration of dialysis was 4 h, and
he dialysate flow was 500 ml/min. To lessen the hemody-
amic changes, 200 ml normal saline priming was admin-
stered before dialysis and no fluid removal was prescribed in
he dialysis group. The radiocontrast medium was nonionic
ohexol (Omnipaque, GE Healthcare Technologies,
Abbreviations
and Acronyms
CAG  coronary
angiography
CN  contrast nephropathy
Cr  serum creatinine
CrCl  creatinine clearance
ESRD  end-stage renal
diseaseaukesha, Wisconsin), and the dose was recorded. pollow-up. Creatinine clearance (CrCl) was measured by
4-h urine collection before and on the fourth day after
oronary angiography. Additional measurements of Cr were
erformed in patients with acute renal failure (defined as an
ncrease of Cr on the fourth day of more than 25% from
aseline) every other day until dialysis started or renal
unction recovered and at discharge in all patients who did
ot need dialysis. Biochemical data were analyzed at a
entral laboratory. The primary end point was the change in
rCl between baseline and the fourth day. Secondary end
oints were the differences in Cr levels on the fourth day
rom baseline, peak Cr level during hospitalization, and Cr
evel at discharge. The numbers of patients with an increase
n Cr level at discharge of at least 1.0 mg/dl above baseline
nd of patients that required emergent and permanent
ialysis were also recorded. Emergent dialysis was per-
ormed if there was oliguria for more than 48 h despite the
dministration of more than 1,000 mg intravenous furo-
emide per day or if the level of serum potassium remained
6 mEq/l with or without electrocardiogram change de-
pite the administration of oral kayexalate. Hemodialysis
as discontinued when there was evidence of recovery of
enal function, with the restoration of urine amount of
500 ml/day and improvement of CrCl 5 ml/min/
.73 m2. The need for permanent dialysis was persistent
ith CrCl 5 ml/min/1.73 m2.
tatistical analysis. When calculating sample size, we
ssumed a baseline CrCl of 12 ml/min/1.73 m2. Assuming
decrease in the CrCl of 5 percent for the dialysis group,
0% for the control group and a common standard deviation
f the decrease of 2.2 ml/min/1.73m2; the inclusion of 34
ubjects in each group allowed for a 2-sided significance
evel of 5% and 90% power. The data are expressed as
ean  SD or as proportions. To compare baseline
ariables between the 2 groups, Fisher exact test for cate-
oric variables and Student unpaired t test for continuous
ariables were used. Changes in Cr values in the dialysis and
ontrol groups were assessed using repeated-measures anal-
sis of covariance. Statistical analysis of the decrease in the
rCl from baseline to day 4 was performed using multiple
egression. The covariates were age, gender, diagnosis of
iabetes mellitus, hypertension, type of procedure, dose of
ontrast medium, prophylactic dialysis, and baseline CrCl.
ge, contrast medium dose, and baseline CrCl were exam-
ned as continuous variables. A p value of 0.05 was
onsidered to be of statistical significance. All calculations
ere computed with the aid of the SPSS 10.0 software
ackage (SPSS Inc., Chicago, Illinois).
esults
total of 3,724 patients who received coronary angiography
ere consecutively screened, and 318 patients had chronic
enal insufficiency. Eighty-eight patients had ESRD necessi-
ating chronic dialysis, 122 patients had Cr 3.5mg/dl, 18
atients refused to enter the study, and 90 were enrolled. They
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September 11, 2007:1015–20 Hemodialysis Prevents Contrast Nephropathyere randomized into 2 groups. After excluding patients of
nsufficient follow-up (n  3), receiving nonsteroid anti-
nflammatory drugs (n  2), receiving N-acetylcysteine (n 
), and receiving another contrast examination within 48 h
n  1), 42 receiving prophylactic hemodialysis after coronary
ngiography and 40 receiving fluid supplement only were
ncluded in the analyses (Table 1). The 2 groups were similar
ith respect to demographic and baseline clinical characteris-
ics. Among the patients in the dialysis group, dialysis was
nitiated at an interval of 81 32 min, ranging from 45 to 180
in, after exposure to the contrast medium.
The baseline CrCl was similar in the dialysis (13.2
l/min/1.73 m2) and control (12.6 ml/min/1.73 m2)
roups; however, the CrCl on the fourth day after coronary
ngiography in the dialysis group was significantly higher
han that in the control group (Table 2). The decrease in
rCl within 72 h after the procedure was 0.4 ml/min/1.73 m2
n the dialysis group and 2.2 ml/min/1.73 m2 in the control
roup (p  0.001) (Table 2).
Multiple regression analysis shows that only prophylactic
ialysis and baseline CrCl were significantly associated with
change in CrCl (Table 3). The control group was
ignificantly associated with a decrease in CrCl of 1.938
l/min/1.73 m2. Every 1-ml/min/1.73 m2 decrease in
aseline CrCl was significantly associated with a decrease in
rCl of 0.324 ml/min/1.73 m2. There is no association
etween the change in CrCl and other risk factors such as
ge, gender, diabetes, hypertension, type of procedure, or
linical Characteristics of the Patients
Table 1 Clinical Characteristics of the Patients
Dialysis Group
(n  42)
Control Group
(n  40) p Value
Age (yrs) 65.3 11.1 65.9 11.2 0.780*
Male 27 (64%) 26 (65%) 0.946†
Body weight (kg) 63.7 10.2 61.0 10.0 0.220*
Systemic hypertension 40 (95%) 37 (93%) 0.604†
Diabetes mellitus 23 (55%) 25 (62%) 0.477†
Coronary artery disease 0.600†
Stenosis 50% 3 (7%) 1 (3%)
Single-vessel 16 (38%) 12 (30%)
Double-vessel 8 (19%) 10 (25%)
Triple-vessel 15 (36%) 17 (42%)
Prior myocardial infarction 10 (24%) 7 (18%) 0.481†
Left ventricular ejection fraction 0.45 0.07 0.42 0.08 0.221*
Use of ACE inhibitors 11 (26%) 11 (28%) 0.894†
Indication for CAG 0.812†
Stable angina 22 (52%) 22 (53%)
Acute coronary syndrome 20 (48%) 18 (47%)
Performed procedure 0.837†
Coronary angiography 19 (45%) 19 (47%)
Percutaneous coronary
intervention
22 (55%) 21 (53%)
Volume of contrast medium (ml) 106.8 44.0 108.1 32.6 0.877*
ata are presented as n (%) or mean SD. *Student unpaired t test was used for the comparison
etween the groups. †Fisher exact test was used for the comparison between the groups.
ACE  angiotensin-converting enzyme; CAG  coronary angiogram.ose of contrast medium. SFigure 1 shows the time course of renal function in the
groups. In the control group, the mean Cr concentra-
ion increased significantly after coronary angiography
nd maintained higher than baseline values at hospital
ischarge in those patients who did not need permanent
ialysis. After angiography in the dialysis group, the Cr
oncentrations were slightly increased on day 4 (4.9  1.3
g/dl vs. 5.1  1.3 mg/dl; p  0.06) but were signifi-
antly increased only at peak value (5.3  1.5 mg/dl; p 
.008). No significant changes from baseline values in
enal function were observed at discharge (5.1  1.3
g/dl). The renal function of patients in the dialysis
roup was better preserved over the whole course after
AG compared with the control group.
One patient (2%) in the dialysis group and 14 patients
35%) in the control group required temporary dialysis after
AG (p  0.001) (Fig. 2) during hospitalization. The
ength of time between contrast exposure and initiation of
ialysis was 5  3 days (range 1 to 13 days). Ten of the
atients recovered and stopped hemodialysis within 3 weeks
range 1 to 21 days). No patients in the dialysis group, but
in the control group (13%), required maintenance dialysis
fter discharge (number needed to treat [NNT] 8; p 
.018). For the patients who did not require chronic
ialysis, the mean Cr level at discharge was higher, but not
ignificantly, in the control group than in the dialysis group
5.9 2.5 mg/dl vs. 5.1 1.4 mg/dl; p 0.113). However,
8 patients in the control group (45%), but only 2 in the
ialysis group (5%), had permanent renal damage with an
ncrease in Cr concentration greater than 1 mg/dl or
equired permanent dialysis after discharge (risk ratio 2.80,
5% confidence interval 1.24 to 4.35, NNT 2.5; p 0.001).
he length of hospital stay was considerably shorter in the
ialysis group compared to that in the control group (6  3
ays vs. 13  18 days; p  0.017).
No major complications were associated with the
ialysis or the catheter in the dialysis group. Only 1
atient developed minor bleeding from the puncture site
f the femoral catheter; the bleeding stopped easily after
emoval of catheter and there was no need for a blood
ransfusion.
hanges in Renal Functionrom Baselin to Day 4 (Mean  SD)
Table 2 Changes in Renal FunctionFrom Baseline to Day 4 (Mean  SD)
Dialysis
Group
(n  42)
Control
Group
(n  40)
p
Value
Baseline plasma creatinine (mg/dl) 4.9 1.3 4.9 1.6 0.936
Baseline creatinine clearance
(ml/min/1.73 m2)
13.2 3.6 12.6 4.4 0.528
Day 4 creatinine clearance
(ml/min/1.73 m2)
12.8 3.5 10.4 4.4 0.008
Change in creatinine clearance
from baseline to day 4
(ml/min/1.73 m2)
0.4 0.8 2.2 2.8 0.001tudent unpaired t test was used for the comparison between the groups.
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atients with chronic renal failure are prone to atheroscle-
otic cardiovascular diseases (17), and renal dysfunction
ccounts for the greatest risk factor in developing CN after
AG. Once CN occurred, 36% to 60% of these high-risk
atients required emergent dialysis, and the hospital stay
as prolonged to an average of 17 days (18,19). Of these
atients, 28% to 33% did not recover and needed mainte-
ance dialysis. Therefore, the cardiologist usually has to
ake a difficult choice between alleviating coronary syn-
romes by coronary intervention and the risk of acute renal
ailure in patients with pre-existing renal dysfunction. Based
n the present results, prophylactic hemodialysis immedi-
tely after CAG appears to be an effective and safe strategy
Figure 1 Cr Levels Before Coronary Angiography, on Day 4,
at Peak Value, and at Hospital Discharge
Changes in serum creatinine (Cr) values in the dialysis and control groups were
assessed using repeated-measures analysis of covariance. Multiple compari-
sons with the Bonferroni t test were used for the comparisons between and
within groups. For the interaction between time and treatment in terms of the
Cr level, F statistic  22.9 (p  0.001). Changes from baseline in the Cr level
were significant at the peak value in the dialysis group (***p  0.008) and on
day 4, at the peak value, and at discharge in the control group (*p  0.001);
the difference between the 2 groups was significant on day 4 and at peak
value (**p  0.010 on day 4; p  0.005 at peak value).
Factors Associated With Change in CreatinineClearance From Basel ne to Day 4 for All Patien
Table 3 Factors Associated With Change inClearance From Baseline to Day 4 f
Unstandard
Coefficien
Age (1-yr increase) 0.001
Male 0.645
Diabetes mellitus 0.169
Hypertension 0.241
PCI 0.203
Dose of contrast medium (1-ml increase) 0.003
Prophylactic dialysis 1.938
Baseline creatinine clearance
(1-ml/min/1.73 m2 increase)
0.324
PCI  percutaneous coronary intervention.o improve renal outcome in patients with advanced renal
ailure who need CAG.
Some may argue that either the Cr level or CrCl could
epresent the glomerular filtration rate (GFR) only at a
teady state. Because it is the change in GFR rather than the
bsolute GFR level that we wanted to measure, and because
he change in Cr level reflects the change in GFR faithfully,
e chose the changes in Cr level and CrCl to evaluate the
hange in renal function after CAG in the present study.
he only pitfall was that the Cr level in the dialysis group
ould be artificially lower immediately after prophylactic
emodialysis. According to an earlier study (20), Cr levels in
he dialysis group would catch up with baseline levels and
he levels in the control group within 3 days. Therefore, we
sed the changes in Cr level or CrCl of day 4 from baseline
o express the change in GFR. Besides, using our secondary
nd points, including the number of patients who needed
ither temporary or long-term dialysis after CAG and the
hanges in Cr level at discharge, prophylactic hemodialysis
fter CAG also showed significantly better results in the
ialysis group.
Figure 2 Renal Outcomes of Dialysis and Control Groups
The bars show significantly different percentages of dialysis and control
patients who needed subsequent dialysis (2% vs. 35%; p  0.001), patients
who needed permanent dialysis (0 vs. 13%; p  0.018), and those with an
increase in serum creatinine level between baseline and discharge of at least
1.0 mg/dl (5% vs. 37%; p  0.001). Fisher exact test was used for the com-
parison between the groups.
2  0.260)
tinine
l Patients (R2  0.260)
Standardized
Coefficient B
95% Confidence
Interval p Value
0.001 0.043 to 0.043 0.991
0.140 0.465 to 1.755 0.251
0.038 1.206 to 0.868 0.746
0.026 2.310 to 1.827 0.817
0.499 0.791 to 1.197 0.685
0.040 0.015 to 0.010 0.716
0.440 1.040 to 2.837 0.001
0.180 0.042 to 0.318 0.011ts (R
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September 11, 2007:1015–20 Hemodialysis Prevents Contrast NephropathyThe underlying mechanism of CN is not clear. A reduction
n renal perfusion caused by a direct effect of the contrast
edium on the kidney and toxic effects on the tubular cells are
enerally accepted as the main factors in the pathogenesis of
N (21). In patients with renal insufficiency, delayed excretion
f the contrast medium has led to concerns about increased
oxicity after CAG. Although the concentration of the
ontrast medium can be effectively reduced by hemodialysis
ithin short periods (22–25), the effect of prophylactic
emodialysis in preventing CN addressed in earlier studies
s still controversial (20,26). Different doses of contrast
edia, small sample sizes, and variations in residual renal
unction might be causes of bias. Moreover, nephrotoxicity
ue to dialysis per se has been linked with the activation of
nflammatory reactions by the dialyzer and the induction of
ypovolemia and hypotension during dialysis. It is possible
hat the nephrotoxic effect of hemodialysis might have offset
he beneficial effect of the removal of the contrast medium.
n the present study, all of the possible nephrotoxic factors
ere eliminated.
The overwhelming positive effect of our study may be due
o the high-risk population we chose; all of our patients had
residual CrCl of 25 ml/min/1.73 m2, which made the
idney very vulnerable to any further injury. Thus, the rapid
emoval of nephrotoxic contrast agents by hemodialysis was
ramatically shown to be of great benefit. Considering that
emodialysis is an invasive procedure—although we cannot
learly indicate the critical level of residual CrCl at which
rophylactic hemodialysis will be beneficial from the results
f the present study—we strongly suggest that patients with
CrCl of 25 ml/min/1.73 m2 receive prophylactic hemo-
ialysis after CAG to prevent permanent renal injury.
ecause the incidence of permanent renal injury in the
ialysis group was very low (2 of 42 patients), there was no
ignificant association between exposure time to the contrast
edium and renal injury (data not shown). We were not
ble to ascertain how long after the exposure time to the
ontrast medium the prophylactic hemodialysis would still
e effective. From our study, it was speculated that starting
rophylactic hemodialysis within 180 min after exposure might
e acceptable when low-dose contrast media (150 ml) are
sed.
The present study is designed to examine the preventive
ffect of hemodialysis in advanced renal failure patients after
AG. Because the dose of contrast medium of diagnostic
omputer tomography is usually150 ml and the procedure
s normally180 min, it is reasonable to apply our results to
his population who need receive diagnostic computerized
omography.
In contrast to hemodialysis, continuous venovenous he-
ofiltration (CVVH) before and after CAG has also been
roposed as being effective in preventing CN (27,28).
onsidering the relatively high cost and time-consuming
ature of this procedure, the limited availability of beds in
ntensive care units, the lengthy immobilization of patients,
nd the pharmacokinetics of contrast media during dialysis25), hemodialysis might be more practicable than CVVH
o prevent CN after CAG.
tudy limitations. Our study was not blinded. The poten-
ial effective strategies to prevent CN had been imple-
ented in both groups, including fluid supplement, low-
smolality contrast media, and a lower dose of contrast
gents, and there was still shown to be a significant benefit
f prophylactic hemodialysis. However, the influence of the
ouble dose of N-acetylcysteine and hemodialysis to prevent
N requires further investigation.
onclusions
ur findings suggest that prophylactic hemodialysis in
atients with advanced chronic renal failure undergoing
oronary angiography reduces the intensity of acute renal
eterioration due to contrast medium exposure, shortens
ospital stay, and improves renal outcome.
eprint requests and correspondence to: Dr. Hua-Chang Fang,
ivision of Nephrology, Kaohsiung Veterans General Hospital,
86 Ta-Chung First Rd, Kaohsiung, Taiwan 813. E-mail:
cfang@isca.vghks.gov.tw.
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